What's Happening?
Genentech has announced new data from a five-year study showing that Susvimo, a continuous delivery treatment for wet age-related macular degeneration (AMD), maintains vision with two refills per year. The Phase III Portal study, an extension of the Archway study, demonstrated that Susvimo provides sustained vision outcomes and retinal stabilization in approximately 95% of patients. The treatment was well tolerated over the study period, offering a reliable alternative to frequent eye injections. The findings were presented at the American Society of Retina Specialists Annual Meeting, reinforcing Susvimo's potential to improve real-world outcomes for patients with wet AMD.
AD
Why It's Important?
Wet AMD is a leading cause of vision loss among people over 60 in the U.S., affecting millions. The study's results suggest that Susvimo could significantly reduce the burden of frequent injections, improving patient compliance and quality of life. This advancement in treatment could lead to better long-term vision preservation for those affected by wet AMD, potentially reducing healthcare costs associated with managing the condition. The data supports Genentech's commitment to developing innovative solutions for serious eye diseases.
What's Next?
Genentech may seek to expand the use of Susvimo based on these promising results, potentially influencing treatment protocols for wet AMD. The company might also explore further applications of the Port Delivery Platform for other retinal diseases. Regulatory bodies and healthcare providers could consider integrating Susvimo into standard care practices, given its demonstrated efficacy and safety profile.
